Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition

Drug

Spasticity

Online since 8 September 2023, updated 313 days ago

About this trial

The trial is enrolling 90 individuals with chronic cervical or thoracic spinal cord injuries to test the effect of a drug, Riluzole, on spasticity. If included, participants will receive either: 1) four varying doses of Riluzole; or 2) a placebo drug. Final testing of blood samples to determine effective dosing of Riluzole will be performed after 2 months.

Included participants

Gender

All

Age

18 - 65 years

Injury level

C4 - T12

Severity (AIS)?

AIS-A

AIS-B

AIS-C

AIS-D

Time since injury

12 months - 65 years

Injury type

Traumatic

Healthy volunteers

C4-T12

Additionally, participants must

present with spasticity

What’s involved

Type

Drug

Details

Participants will receive either - 1) four doses of the active drug (Riluzole) or - 2) the placebo drug. - Final testing of blood samples will be performed after 2 months.

Potential benefits

Main benefits

Spasticity

Additional benefits

General health

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results